Belharra Gets $130M from Versant, Genentech For Chemoproteomic Discovery

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Santa Ana Bio Debuts with $168M to Develop Precision Inflammatory Medicines
SixPeaks Snags $110M from Versant, AZ for Drugs to Preserve Muscle and Shed Fat
The Small Molecule Drug Discovery Renaissance: Jeff Jonker on The Long Run
Versant-Backed Nexo Gets $60M to Pursue Tough Cancer Targets